




Figure S1. Waterfall plot of best change in target-lesion size from baseline of 32 eligible patients. Red dash line indicates the threshold of partial response (PR).





Figure S2. Overall survival of patients in different clinical responses (A) and in different pathological responses (B). RECIST CR: complete response, PR: partial response, SD: stable disease. JGCA TRG grade 1: slight effect, grade 2: considerable effect, grade 3: complete response.





Figure S3. (A) Event-free survival (EFS) and (B) overall survival (OS) of patients received different doses of apatinib.





Figure S4. (A) Event-free survival (EFS) and (B) overall survival (OS) of patients with or without adverse events. AEs: adverse events.





Figure S5. (A) Event-free survival (EFS) and (B) overall survival (OS) of patients received XELOX or XELOX plus apatinib. XELOX+A: XELOX plus apatinib; patients received XELOX alone from the NEO-CLASSIC study [29].